What question did this study set out to answer?

The study aims to evaluate the efficacy of pegcetacoplan in patients with lower baseline proteinuria.

March 28, 2026Open Access

Wcn26-9116 Efficacy of Pegcetacoplan in Patients With Lower Baseline Proteinuria: A Subgroup Analysis From the Valiant Trial

Resultado clave

Pegcetacoplan treatment for 52 weeks demonstrated consistent clinical efficacy and sustained benefit in adolescents, matching the overall VALIANT trial population.

Puntos clave

The study aims to evaluate the efficacy of pegcetacoplan in patients with lower baseline proteinuria.
Conducted a subgroup analysis from the VALIANT trial.
Evaluated clinical efficacy over a 52-week treatment period.
Included adolescents as a specific focus group.
Efficacy of pegcetacoplan was consistent with the overall VALIANT population.
Demonstrated sustained benefits over 52 weeks in treated adolescents.

PICO estructurado

Does pegcetacoplan reduce proteinuria in patients with C3G and IC-MPGN with lower baseline proteinuria?

Población

Patients with C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) with baseline proteinuria ≤1.5 g/g

Intervención

Pegcetacoplan (subcutaneous infusion twice weekly)

Comparador

Placebo

Resultado

Change from baseline to Week 26 in log-transformed urine protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR)surrogate

Pegcetacoplan demonstrated clinically meaningful reductions in proteinuria in patients with C3G and IC-MPGN with lower baseline proteinuria (≤1.5 g/g).

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

Conclusion: Clinical efficacy of 52 weeks of pegcetacoplan treatment for adolescents was consistent with the overall population of VALIANT, confirming its sustained benefit in broad patient populations.

Me gusta

Guardar

Ver artículo completo